START AND STAY WITH BRIVIACT FOR
PEDIATRIC PATIENTS
Available for patients as young as 1 month of age1
BRIVIACT® (brivaracetam) CV is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.1
Available in multiple formulations with no required titration1
Products not shown at actual size.
BRIVIACT injection may be used when oral administration is temporarily not feasible.1
RETENTION
One year after starting treatment, an estimated 7 in 10 pediatric patients remained on BRIVIACT2
KAPLAN-MEIER ESTIMATE OF PERCENTAGE OF PEDIATRIC PATIENTS WITH FOCAL SEIZURES (N=168) REMAINING ON TREATMENT IN A POOLED STUDY2
*Kaplan-Meier estimates of the percentage of subjects completing only the specified duration of treatment with BRIVIACT regardless of any discontinuation reason.2
This long-term retention data is an estimation of how long patients have remained on treatment in select BRIVIACT clinical studies. Conclusions of long-term efficacy or safety should not be drawn based on this data.
Two years after starting treatment, an estimated 6 in 10 pediatric patients remained on BRIVIACT2
Study design2,3
- Pooled data from Phase 2a and Phase 3a open-label trials of BRIVIACT
- Patients aged ≥1 month to <17 years (N=219), uncontrolled by 1-3 prior ASMs
- Out of 219 patients, 168 had focal seizures
- After dose adjustment, patients received BRIVIACT 1 to 5 mg/kg/day (maximum 200 mg/day)
EFFICACY
BRIVIACT efficacy extrapolated for pediatric patients1
Efficacy in adults was established without a titration period1
Adult efficacy data
Adult pivotal trial design1
- Effectiveness was established in 3 fixed-dose, randomized, double-blind, placebo-controlled, multicenter studies, which included 1550 adult patients
- Enrolled adult patients had focal seizures that were not adequately controlled by 1 to 2 concomitant AEDs
- Patients taking concomitant levetiracetam were excluded from Study 3
AED=antiepileptic drug.
BRIVIACT efficacy was also studied in pediatric patients4
Pediatric study design4
- Phase 2a, open-label, single-arm, fixed 3-step dose-escalation trial
- Short-term safety and tolerability, pharmacokinetics, preliminary efficacy of BRIVIACT oral solution. Efficacy analyses were exploratory
- Pediatric patients 1 month to <16 years of age
- 1-week baseline period, 3-week evaluation period
Additional study design
- In the treatment period, BRIVIACT oral solution dosage was divided into 2 daily doses and increased each week to approximately 0.8, 1.6, and 3.2 mg/kg/day for patients aged ≥8 years, and 1.0, 2.0, and 4.0 mg/kg/day for patients aged <8 years4
- 99 patients were enrolled in the trial; 52 patients with focal seizures were included in the safety analysis, and 50 were included in the efficacy analysis. Only those patients experiencing seizures in the one-week baseline period (n=37) were included in the seizure reduction and responder rate analyses. All 50 focal seizure patients were included in the seizure freedom analysis4
Demographic data
BRIVIACT was studied in a challenging pediatric population with focal seizures1,4
Pediatric trial results4
EFFICACY WAS EVALUATED OVER A 3‑WEEK PERIOD
30%
OF PATIENTS
experienced a ≥50%
reduction in seizure
days from baseline†
Based on treatment responses
seen in patients with focal
seizures (11/37; <16 years old).
24%
OF PATIENTS
achieved complete
seizure freedom over
a 3-week period‡
As seen in patients (12/50) with
focal seizures.
†Patients without seizure in baseline were excluded. Number of seizure days standardized to a 28-day duration.
‡With or without secondary generalization and no primary generalized seizures at baseline.
SAFETY
In adult adjunctive trials, most adverse events with BRIVIACT were reported to be mild or moderate2
The safety profile of BRIVIACT was established in adults in phase 3 placebo-controlled trials1
Most common adverse reactions in adults
Most common adverse reactions that occurred in ≥5% for BRIVIACT
and at least 2% more frequently than placebo1
The safety profile for pediatric patients was
similar to adults1
- BRIVIACT has been shown to be generally well tolerated for infants
1 month of age and older2
The most common drug-related treatment-emergent adverse events (TEAEs) in pooled pediatric studies (≥5%)2
Phase 2a and phase 3a
open-label study design
STUDY DESIGN:
Pooled safety data from phase 2a and phase 3a open-label trials of BRIVIACT in patients aged 1 month to <17 years (N=219), uncontrolled by 1 to 3 AEDs. Of the 219 patients, 168 had focal seizures. After dose adjustment, patients received BRIVIACT 1 to 5 mg/kg/day (maximum 200 mg/day).2,3
BRIVIACT injection safety and tolerability is consistent with oral formulations1
- The safety and tolerability of BRIVIACT IV has been evaluated as a 15-minute infusion or a bolus (up to 2-minute) injection in an open-label study in children aged 2 months to <16 years with epilepsy1,2
- The safety and pharmacokinetics of BRIVIACT were similar in the infusion and bolus injection groups2
- Adverse reactions with BRIVIACT injection in adult and pediatric patients were generally similar to those observed with BRIVIACT tablets. Other adverse events that occurred in adult patients who received BRIVIACT injection included dysgeusia, euphoric mood, feeling drunk, and infusion site pain1
BEHAVIOR & CONDITION
Behavioral and cognitive stability with BRIVIACT: Pediatric measures were generally unchanged from baseline2
Based on 2 established neurological measurement tools5,6
- Parents or caregivers completed the BRIEF® and Achenbach Child Behavior Checklist (CBCL) surveys at regular intervals during the long-term, phase 3a, follow-up study. The version appropriate for the patient’s age at each visit was completed2,3
Study design2,3
Study design for evaluating BRIEF® and Achenbach CBCL
- Pooled interim analysis from phase 2a and phase 3a open-label trials
- Included pediatric patients 1 month to <17 years (N=219) uncontrolled by 1 to 3 AEDs
- Of the 219 patients, 168 had focal seizures
- Parents or caregivers completed the BRIEF® and Achenbach CBCL surveys at regular intervals during the long-term, phase 3a, follow-up study. The version appropriate for the patient’s age at each visit was completed
- AED changes were permitted over the duration of the long-term follow-up study
- Additional factors may influence measures of behavior and cognition
Executive function and self-regulation categories§ remained stable for the majority of school-aged children (aged 5 to ≤17 years), relative to baseline2
BRIEF® GLOBAL EXECUTIVE COMPOSITE SCORE CATEGORY CHANGES (N=92)2§
§T-score categories were defined as “normal” (0 to <50), “borderline” (50 to <65), and “clinically significant” (≥65).
BRIEF=Behavior Rating Inventory of Executive Function.
Emotional, behavioral, and social problem categoriesII remained stable among the majority of school-aged children (aged 6 to <17 years), relative to baseline2
SHIFT IN CHILD BEHAVIOR CHECKLIST T-SCORE CATEGORIES (N=127)II
A similar trend was observed among patients aged 1½ months to 5 years who were assessed by a separate CBCL.
PSYCHIATRIC ADVERSE REACTIONS: BRIVIACT causes psychiatric adverse reactions, including non-psychotic and psychotic symptoms. These events were reported in approximately 13% of adult patients taking at least 50 mg per day of BRIVIACT compared to 8% of adult patients taking placebo. A total of 1.7% of adult patients taking BRIVIACT discontinued treatment due to psychiatric reactions compared to 1.3% of patients taking placebo. Psychiatric adverse reactions were also observed in open-label pediatric trials and were generally similar to those observed in adults. Advise patients to report these symptoms immediately to a healthcare provider.1
DOSING
A therapeutic dose on day 1 with the simplicity of no required titration1
For your pediatric patients with focal seizures, you can start with a therapeutic dose on day 1 with BRIVIACT and have room to adjust if needed based on clinical response and tolerability.
The recommended dosing regimen is dependent upon body weight for patients weighing less than 50 kg.
Recommended dosage
Multiple formulations for pediatric patients1
SIMPLE 1:1 DOSE CONVERSION
Products not shown at actual size.
BRIVIACT oral solution and tablets1
Can be given with or without food
Tablets should be swallowed whole with liquid. They should not be chewed or crushed
No blood level, respiratory, or cardiac monitoring required
Intravenous injection only1
- BRIVIACT injection may be used when oral administration is temporarily not feasible
- BRIVIACT injection should be administered intravenously at the same dosage and same frequency as BRIVIACT tablets and oral solution
- No refrigeration required
- Can be stored in PyxisTM or Omnicell systems
BRIVIACT injection offers rapid administration
Median Tmax following a 2-minute bolus (administered undiluted) is <5 minutes7
Can be administered intravenously over 2 to 15 minutes1
No dilution required1
UCB provides multiple resources for eligible patients starting on BRIVIACT
Learn more about savings & support